NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. (NRSN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nrsn · stock forecast · 2 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.75
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.73 | ↓ 3.37% |
1-day model range: $0.72–$0.73. Peak: $0.73 (-3.37%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $0 | -38.9% |
| 2028 | $0 | -50.7% |
| 2029 | $0 | -55.5% |
| 2030 | $0 | -57.7% |
| 2031 | — | -58.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NRSN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-08 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-25 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-17 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-09 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-12-22 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-11-24 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-08-15 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-07-10 | D. Boral Capital | Maintains | Buy→Buy |
| 2024-12-16 | Maxim Group | Downgrade ↓ | Buy→Hold |
Wall Street analysts have recently issued updated ratings on NeuroSense Therapeutics Ltd. (NRSN) stock. Of the recent 9 rating actions, 0 were upgrades and 1 were downgrades. 2 analysts currently cover NRSN.
Analyst Recommendation Trends
NRSN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 94.7% YoY
Revenue Next Year
$3M
↑ 359.0% YoY
EPS This Year
$-0.39
EPS Next Year
$-0.82
↑ 113.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast NRSN EPS of $-0.39 for the current fiscal year, based on estimates from 1 analysts. The NRSN revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NRSN stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NRSN price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The NRSN short-term stock prediction for tomorrow is $0.73 (-3.37%). The NRSN stock price prediction for 2027 estimates an average of $0. The NRSN stock prediction for 2030 projects a range of $0–$0.
NeuroSense Therapeutics Ltd. trades on NASDAQ under the ticker NRSN. The NRSN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
NRSN forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month NRSN price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.75.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.